Palatin Announces Completion of Patient Enrollment in Phase 2 Study of Orally Administered Melanocortin Agonist PL8177 in Ulcerative Colitis
Portfolio Pulse from
Palatin Technologies has completed patient enrollment for its Phase 2 study of PL8177, an orally administered melanocortin agonist, for treating ulcerative colitis. The treatment aims to offer a safer alternative to current therapies. Results are expected in Q1 2025.
November 25, 2024 | 12:45 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Palatin Technologies has completed enrollment for its Phase 2 study of PL8177, a potential new treatment for ulcerative colitis. This milestone could lead to a safer treatment option, with data expected in Q1 2025.
The completion of patient enrollment in a Phase 2 study is a significant milestone for Palatin Technologies. If successful, PL8177 could offer a safer treatment for ulcerative colitis, potentially boosting investor confidence and positively impacting the stock price. The anticipation of data in Q1 2025 adds a timeline for potential developments.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100